Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6673
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Hepatitis C in healthcare personnel: secondary data analysis of therapies with direct-acting antiviral agents ; volume:13 ; number:1 ; day:25 ; month:5 ; year:2018 ; pages:1-8 ; date:12.2018
Journal of occupational medicine and toxicology ; 13, Heft 1 (25.5.2018), 1-8, 12.2018
- Urheber
-
Westermann, Claudia
- Beteiligte Personen und Organisationen
-
Wendeler, Dana
Nienhaus, Albert
SpringerLink (Online service)
- DOI
-
10.1186/s12995-018-0197-6
- URN
-
urn:nbn:de:101:1-2018080515403227319331
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:23 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Westermann, Claudia
- Wendeler, Dana
- Nienhaus, Albert
- SpringerLink (Online service)
Ähnliche Objekte (12)
Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C
Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C
Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments
Utility of the new cobas HCV test for viral load monitoring during direct-acting antiviral therapy
Hepatitis C in healthcare personnel: follow-up analysis of treatments with direct-acting antiviral agents
Direct-Acting Antiviral Therapy for Hepatitis C: Attitudes Regarding Future Use
Hepatic steatosis in HCV-infected persons in the direct-acting antiviral era
Direct-acting antiviral resistance of Hepatitis C virus is promoted by epistasis
Adoption of direct-acting antiviral medications for hepatitis C: a retrospective observational study
HCV and kidney transplant in the era of new direct-acting antiviral agents (DAAs)
Acute reversible rhabdomyolysis during direct-acting antiviral hepatitis C virus treatment: a case report
Modeling HIV-HCV coinfection epidemiology in the direct-acting antiviral era: the road to elimination
Direct-acting antiviral treatment downregulates immune checkpoint inhibitor expression in patients with chronic hepatitis C
Perceived physical health outcomes of direct-acting antiviral treatment for hepatitis C: a qualitative study
The role of a hepatitis C virus vaccine: modelling the benefits alongside direct-acting antiviral treatments